Señales en vivo de LEGN | Maximiza tus Ganancias con Getagraph.com

COMPRAR 20207 min ago

@ $52.08

Emitido: 15 abr 2024 @ 14:17

Retorno: -13.39%

Señal anterior: abr 15 - 13:41

Señal anterior: Vender

Retorno: -1.02 %

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 15:04):

Stats
Volumen de hoy	700 597
Volumen promedio	974 846
Capitalización de mercado	8.20B
EPS	$0 ( 2024-03-11 )
Próxima fecha de ganancias	( $-0.240 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.34
ATR14	$0.0350 (0.08%)

Volumen Correlación

Largo: -0.02 (neutral)

Corto: -0.69 (moderate negative)

Signal:(29.312) Neutral

Legend Biotech Corp Correlación

10 Correlaciones Más Positivas
AQST	0.804

10 Correlaciones Más Negativas
MACQU	-0.813
CFACU	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Legend Biotech Corp Correlación - Moneda/Commodity

0.63
( weak )

0.45
( neutral )

0.00
( neutral )

0.66
( moderate )

0.75
( moderate )

-0.89
( strong negative )

Legend Biotech Corp Finanzas

Annual	2023
Ingresos:	$285.14M
Beneficio Bruto:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2023
Ingresos:	$285.14M
Beneficio Bruto:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2022
Ingresos:	$117.01M
Beneficio Bruto:	$51.64M (44.14 %)
EPS:	$-2.81

FY	2021
Ingresos:	$89.79M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.74

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.